Arcus Biosciences, Inc. $RCUS Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 404.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 424,071 shares of the company’s stock after buying an additional 340,048 shares during the period. BNP Paribas Financial Markets’ holdings in Arcus Biosciences were worth $10,106,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Decheng Capital LLC lifted its holdings in shares of Arcus Biosciences by 242.3% during the 3rd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $7,447,000 after acquiring an additional 387,609 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Arcus Biosciences during the 3rd quarter valued at $1,254,000. Candriam S.C.A. acquired a new position in shares of Arcus Biosciences during the 3rd quarter valued at $5,147,000. Vanguard Group Inc. lifted its holdings in Arcus Biosciences by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 6,629,453 shares of the company’s stock worth $90,161,000 after buying an additional 73,210 shares in the last quarter. Finally, Aberdeen Group plc acquired a new position in Arcus Biosciences in the 3rd quarter worth $4,418,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 7,763 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $25.63, for a total value of $198,965.69. Following the completion of the transaction, the chief financial officer owned 84,161 shares in the company, valued at approximately $2,157,046.43. This represents a 8.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at approximately $1,020,002.37. This trade represents a 6.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by corporate insiders.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $23.26 on Tuesday. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a fifty-two week low of $7.91 and a fifty-two week high of $28.72. The firm has a 50-day simple moving average of $23.88 and a 200 day simple moving average of $22.87. The company has a market cap of $2.92 billion, a PE ratio of -7.31 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The business had revenue of $17.00 million for the quarter, compared to the consensus estimate of $29.49 million. During the same period in the prior year, the company earned ($1.14) EPS. Arcus Biosciences’s quarterly revenue was down 39.3% on a year-over-year basis. On average, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RCUS shares. Lifesci Capital started coverage on shares of Arcus Biosciences in a report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the company an “equal weight” rating in a research note on Thursday, February 12th. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Leerink Partners set a $47.00 target price on shares of Arcus Biosciences in a research note on Monday, April 20th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.10.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.